According to Zhitong Finance App, Shiyao Group (01093.HK) announced that the SYS 6077 injection developed by the Group has been approved by the China National Drug Administration to issue a drug clinical trial approval notice, and clinical trials can be carried out in China. The clinical indication approved this time is advanced malignant tumors.

According to Zhitong Finance App, Shiyao Group (01093.HK) announced that the SYS 6077 injection developed by the Group has been approved by the China National Drug Administration to issue a drug clinical trial approval notice, and clinical trials can be carried out in China. The clinical indication approved this time is advanced malignant tumors.